Molecular Templates Inc

NASDAQ:MTEMUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Molecular Templates, Inc. is a clinical stage biopharmaceutical company that is focused on the discovery and development of differentiated, targeted, biologic therapeutics for cancer and other serious diseases. The Company utilizes its biologic drug platform to design and generate engineered toxin bodies (ETBs). ETBs use a genetically engineered version of the Shiga-like Toxin A subunit (SLTA), a ribosome inactivating bacterial protein. The Company is developing ETBs for various targets, including CD20, CD38, HER2, and PD-L1. CD20 is central to B cell malignancies and is clinically validated as a target for the treatment of lymphomas and autoimmune disease. CD38 has been validated as a clinical target in the treatment of multiple myeloma. HER2 is clinically validated as a target for the treatment of solid tumors including breast and gastric cancer. PD-L1 is central to immune checkpoint pathways and is a target expressed in a variety of solid tumor cancers.

Contact Information

Headquarters

9301 Amberglen Blvd Ste 100AUSTIN, TX, United States 78729-1153

Phone

512-896-1555

Fax

302-655-5049

Executives

Independent Chairman of the Board

Harold Selick

President, Chief Operating Officer, Interim Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer

Jason Kim

Chief Executive Officer, Chief Scientific Officer, Director

Eric Poma

General Counsel

Megan Filoon

Chief Medical Officer

Roger Waltzman